Wei Li is a Cardiology physician. ClinicalTrials.gov lists 82 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13237 41st Rd Ste C03
Flushing, NY 113554235
Telephone
347-618-1636Registry record last updated 26 Oct 2015.
Clinical trials
- Music Therapy for Oral Mucositis Pain in Pediatric Patients
Sponsor: University of California, San Francisco
- BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Sponsor: Henan Provincial People's Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Pharming Healthcare, Inc.Program year20251 payment
- Endologix LLCProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
79%Beta blocker24.9%Metoprolol Succinate53%Atenolol27%Carvedilol7%Labetalol Hcl6%Propranolol Hcl4%Metoprolol Tartrate3%Part D<11 patientsStatin15.3%Atorvastatin Calcium76%Simvastatin16%Rosuvastatin Calcium8%Part D<11 patients+ 9 more classes in this area
Blood & clotting
10.3%Factor Xa inhibitor6.2%Eliquis59%Xarelto42%Part D≥15 patientsP2Y12 inhibitor4.1%Clopidogrel100%Part D≥19 patientsMetabolism & gastrointestinal
3.3%Proton pump inhibitor1.5%Omeprazole58%Pantoprazole Sodium42%Part D<11 patientsH2 blocker0.9%Famotidine100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 1997–2026 per NIH RePORTER. The latest:
3 awards on record per NIH RePORTER; the itemized rows are on their way. Why? →
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”